Provides a historical overview of patenting activity for Glycoprotein IIb/IIIa antagonists up to 1996.
No takes yet. Share an insight, caveat, or question.
Historical patent data on GP IIb/IIIa antagonists ends in 1996; leaves open subsequent IP developments for researchers.
Wityak et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: